JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
102 hedge funds and large institutions have $207M invested in Jounce Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 21 increasing their positions, 40 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
48% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 40
Holders
102
Holding in Top 10
2
Calls
$1.72M
Puts
$1.54M
Top Buyers
| 1 | +$7.59M | |
| 2 | +$2.88M | |
| 3 | +$844K | |
| 4 |
HSA
Hussman Strategic Advisors
Ellicott City,
Maryland
|
+$832K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$738K |
Top Sellers
| 1 | -$3.4M | |
| 2 | -$3.27M | |
| 3 | -$2.05M | |
| 4 |
Renaissance Technologies
New York
|
-$1.6M |
| 5 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$1.59M |